Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer

Giampiero Giovacchini, Maria Picchio, Stefano Schipani, Claudio Landoni, Luigi Gianolli, Valentino Bettinardi, Nadia Di Muzio, Maria Carla Gilardi, Ferruccio Faziot, Cristina Messa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aims and background. Evaluation of the metabolic response to radiotherapy in non- small cell lung cancer patients is commonly performed about three months after the end of radiotherapy. The aim of the present study was to assess with positron emission tomography/computed tomography (PET/CT) and [ 18F]fluorodeoxyglucose changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer patients. Methods and study design. In 6 patients, PET/CT scans with [ 18F]luorodeoxyglucose were performed before (PET 0), during (PET 1 at a median of 14 days before the end of radiotherapy) and after the end of radiotherapy (PET 2 and PET 3, at a median of 28 and 93 days, respectively). The metabolic response was scored according to visual and semiquantitative criteria. Results. Standardize maximum uptake at PET 1 (7.9 ± 4.8), PET 2 (5.1 ± 4.1) and PET 3 (2.7 ± 3.1) were all significantly (P 0 (16.1 ± 10.1). Standardized maximum uptake at PET, was significantly higher than at both PET 2 and PET 3. There were no significant differences in SUV miX between PET 2 and PET 3. PET 3 identified 4 complete and 2 partial metabolic responses, whereas PET 1 identified 6 partial metabolic responses. Radiotherapy-induced increased [ 18Fl]luorodeoxyglucose uptake could be visually distinguished from tumor uptake based on PET/CT integration and was less frequent at PET 1 (n = 2) than at PET 3 (n 6). Conclusions. In non-small cell lung cancer, radiotherapy induces a progressive decrease in glucose metabolism that is greater 3 months after the end of treatment but can be detected during the treatment itself. Glucose avid, radiotherapy-induced inflammation is more evident after the end of radiotherapy than during radiotherapy and does not preclude the interpretation of 1'8Flfluorodeoxyglucose images, particularly when using PET/CT.

Original languageEnglish
Pages (from-to)177-184
Number of pages8
JournalTumori
Volume95
Issue number2
Publication statusPublished - Mar 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Glucose
Fluorodeoxyglucose F18
Inflammation
Positron Emission Tomography Computed Tomography
Therapeutics

Keywords

  • Lung cancer
  • Positron- emission tomography
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer. / Giovacchini, Giampiero; Picchio, Maria; Schipani, Stefano; Landoni, Claudio; Gianolli, Luigi; Bettinardi, Valentino; Muzio, Nadia Di; Gilardi, Maria Carla; Faziot, Ferruccio; Messa, Cristina.

In: Tumori, Vol. 95, No. 2, 03.2009, p. 177-184.

Research output: Contribution to journalArticle

Giovacchini, G, Picchio, M, Schipani, S, Landoni, C, Gianolli, L, Bettinardi, V, Muzio, ND, Gilardi, MC, Faziot, F & Messa, C 2009, 'Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer', Tumori, vol. 95, no. 2, pp. 177-184.
Giovacchini, Giampiero ; Picchio, Maria ; Schipani, Stefano ; Landoni, Claudio ; Gianolli, Luigi ; Bettinardi, Valentino ; Muzio, Nadia Di ; Gilardi, Maria Carla ; Faziot, Ferruccio ; Messa, Cristina. / Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer. In: Tumori. 2009 ; Vol. 95, No. 2. pp. 177-184.
@article{95fec241dc624e03903f28f67be391b7,
title = "Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer",
abstract = "Aims and background. Evaluation of the metabolic response to radiotherapy in non- small cell lung cancer patients is commonly performed about three months after the end of radiotherapy. The aim of the present study was to assess with positron emission tomography/computed tomography (PET/CT) and [ 18F]fluorodeoxyglucose changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer patients. Methods and study design. In 6 patients, PET/CT scans with [ 18F]luorodeoxyglucose were performed before (PET 0), during (PET 1 at a median of 14 days before the end of radiotherapy) and after the end of radiotherapy (PET 2 and PET 3, at a median of 28 and 93 days, respectively). The metabolic response was scored according to visual and semiquantitative criteria. Results. Standardize maximum uptake at PET 1 (7.9 ± 4.8), PET 2 (5.1 ± 4.1) and PET 3 (2.7 ± 3.1) were all significantly (P 0 (16.1 ± 10.1). Standardized maximum uptake at PET, was significantly higher than at both PET 2 and PET 3. There were no significant differences in SUV miX between PET 2 and PET 3. PET 3 identified 4 complete and 2 partial metabolic responses, whereas PET 1 identified 6 partial metabolic responses. Radiotherapy-induced increased [ 18Fl]luorodeoxyglucose uptake could be visually distinguished from tumor uptake based on PET/CT integration and was less frequent at PET 1 (n = 2) than at PET 3 (n 6). Conclusions. In non-small cell lung cancer, radiotherapy induces a progressive decrease in glucose metabolism that is greater 3 months after the end of treatment but can be detected during the treatment itself. Glucose avid, radiotherapy-induced inflammation is more evident after the end of radiotherapy than during radiotherapy and does not preclude the interpretation of 1'8Flfluorodeoxyglucose images, particularly when using PET/CT.",
keywords = "Lung cancer, Positron- emission tomography, Radiotherapy",
author = "Giampiero Giovacchini and Maria Picchio and Stefano Schipani and Claudio Landoni and Luigi Gianolli and Valentino Bettinardi and Muzio, {Nadia Di} and Gilardi, {Maria Carla} and Ferruccio Faziot and Cristina Messa",
year = "2009",
month = "3",
language = "English",
volume = "95",
pages = "177--184",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer

AU - Giovacchini, Giampiero

AU - Picchio, Maria

AU - Schipani, Stefano

AU - Landoni, Claudio

AU - Gianolli, Luigi

AU - Bettinardi, Valentino

AU - Muzio, Nadia Di

AU - Gilardi, Maria Carla

AU - Faziot, Ferruccio

AU - Messa, Cristina

PY - 2009/3

Y1 - 2009/3

N2 - Aims and background. Evaluation of the metabolic response to radiotherapy in non- small cell lung cancer patients is commonly performed about three months after the end of radiotherapy. The aim of the present study was to assess with positron emission tomography/computed tomography (PET/CT) and [ 18F]fluorodeoxyglucose changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer patients. Methods and study design. In 6 patients, PET/CT scans with [ 18F]luorodeoxyglucose were performed before (PET 0), during (PET 1 at a median of 14 days before the end of radiotherapy) and after the end of radiotherapy (PET 2 and PET 3, at a median of 28 and 93 days, respectively). The metabolic response was scored according to visual and semiquantitative criteria. Results. Standardize maximum uptake at PET 1 (7.9 ± 4.8), PET 2 (5.1 ± 4.1) and PET 3 (2.7 ± 3.1) were all significantly (P 0 (16.1 ± 10.1). Standardized maximum uptake at PET, was significantly higher than at both PET 2 and PET 3. There were no significant differences in SUV miX between PET 2 and PET 3. PET 3 identified 4 complete and 2 partial metabolic responses, whereas PET 1 identified 6 partial metabolic responses. Radiotherapy-induced increased [ 18Fl]luorodeoxyglucose uptake could be visually distinguished from tumor uptake based on PET/CT integration and was less frequent at PET 1 (n = 2) than at PET 3 (n 6). Conclusions. In non-small cell lung cancer, radiotherapy induces a progressive decrease in glucose metabolism that is greater 3 months after the end of treatment but can be detected during the treatment itself. Glucose avid, radiotherapy-induced inflammation is more evident after the end of radiotherapy than during radiotherapy and does not preclude the interpretation of 1'8Flfluorodeoxyglucose images, particularly when using PET/CT.

AB - Aims and background. Evaluation of the metabolic response to radiotherapy in non- small cell lung cancer patients is commonly performed about three months after the end of radiotherapy. The aim of the present study was to assess with positron emission tomography/computed tomography (PET/CT) and [ 18F]fluorodeoxyglucose changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer patients. Methods and study design. In 6 patients, PET/CT scans with [ 18F]luorodeoxyglucose were performed before (PET 0), during (PET 1 at a median of 14 days before the end of radiotherapy) and after the end of radiotherapy (PET 2 and PET 3, at a median of 28 and 93 days, respectively). The metabolic response was scored according to visual and semiquantitative criteria. Results. Standardize maximum uptake at PET 1 (7.9 ± 4.8), PET 2 (5.1 ± 4.1) and PET 3 (2.7 ± 3.1) were all significantly (P 0 (16.1 ± 10.1). Standardized maximum uptake at PET, was significantly higher than at both PET 2 and PET 3. There were no significant differences in SUV miX between PET 2 and PET 3. PET 3 identified 4 complete and 2 partial metabolic responses, whereas PET 1 identified 6 partial metabolic responses. Radiotherapy-induced increased [ 18Fl]luorodeoxyglucose uptake could be visually distinguished from tumor uptake based on PET/CT integration and was less frequent at PET 1 (n = 2) than at PET 3 (n 6). Conclusions. In non-small cell lung cancer, radiotherapy induces a progressive decrease in glucose metabolism that is greater 3 months after the end of treatment but can be detected during the treatment itself. Glucose avid, radiotherapy-induced inflammation is more evident after the end of radiotherapy than during radiotherapy and does not preclude the interpretation of 1'8Flfluorodeoxyglucose images, particularly when using PET/CT.

KW - Lung cancer

KW - Positron- emission tomography

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=67649127036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649127036&partnerID=8YFLogxK

M3 - Article

C2 - 19579863

AN - SCOPUS:67649127036

VL - 95

SP - 177

EP - 184

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -